 | | Vol. 12.26 – 16 July, 2021 |
| |
|
|
| Scientists identified a novel androgen receptor (AR)/AR-V7 degrader (ARVib) and found that ARVib effectively degraded AR/AR-V7 protein and attenuated AR/AR-V7 downstream target gene expression in prostate cancer cells.
[Oncogene] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers used double-crosslinking to stabilize androgen receptor complexes on chromatin in a castration-resistant prostate cancer cell line.
[Cancer Letters] |
|
|
|
| Human cancer cells treated with STL427944 exhibited increased sensitivity to cytotoxic effects of conventional chemotherapeutic treatments.
[Cell Death & Disease] |
|
|
|
| Investigators characterized and assessed the prognostic potential of distinct immune cell infiltration patterns in the prostate tumor microenvironment.
[Journal of Pathology] |
|
|
|
| The authors identified homeobox B9 as a critical regulator of metastatic prostate cancer stem cells behavior.
[British Journal of Cancer] |
|
|
|
| Scientists investigated the role of FOXA1 in the interactions between prostate cancer cells and endothelial cells.
[Journal of Cancer Research and Clinical Oncology] |
|
|
|
| Researchers investigated the role and underlying mechanism of AGAP2-AS1 in prostate cancer (PCa). AGAP2-AS1 was confirmed to be highly expressed in PCa cells.
[Carcinogenesis] |
|
|
|
| Scientists aimed to elucidate the role of claspin and its relationship with docetaxel resistance in prostate cancer.
[Cancer Medicine] |
|
|
|
| Investigators investigated whether KH176m, a recently discovered selective microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor, could affect prostate cancer cells-derived spheroid growth.
[PLOS One] |
|
|
|
|
| Scientists focus on alterations in the metabolism of prostate cancer, including genetic signatures and molecular pathways associated with metabolic reprogramming.
[British Journal of Cancer] |
|
|
|
| The authors provide an update on the different types of prostate stromal cells, their interrelationships and implications for prostate development, physiology and pathological conditions.
[Prostate] |
|
|
|
|
| Advaxis, Inc. announced the initiation of its Phase I clinical study evaluating ADXS-504 in patients with biochemically recurrent prostate cancer.
[Advaxis, Inc.] |
|
|
|
|
| September 6 – 10, 2021
Virtual |
|
|
|
|
|
| | University of Rochester – Rochester, New York, United States |
|
|
|
| | Augusta University – Augusta, Georgia, United States |
|
|
|
| | Medical University of South Carolina – Charleston, South Carolina, United States |
|
|
|
| | Henry M Jackson Foundation for the Advancement of Military Medicine – Bethesda, Maryland, United States |
|
|
|
| | Mayo Clinic Health System – Rochester, Minnesota, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
